Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysisReview Published on 2022-04-262023-06-24 Journal: Vaccine [Category] 신종인플루엔자, [키워드] biological drugs Chronic diseases Efficacy immunogenicity Safety Vaccine [DOI] 10.1016/j.vaccine.2022.03.041 [Article Type] Review
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project이탈리아의 분산 다중 데이터베이스 의료 네트워크를 통한 면역 매개 염증성 질환에 대한 생물학적 약물의 대규모 시판 후 감시: The VALORE 프로젝트Article Published on 2021-11-012022-09-12 Journal: BioDrugs : clinical immunotherapeutics, biopharmac [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome adverse event age Analysis approved association Biological biological drug biological drugs calculated Compound conducted coronavirus cumulative database drug event Follow-up Frequency highest Immune-mediated inflammatory disease incidence rate Inclusion Infection infections inhibitor investigated Italian Italian region Italian regions lowest malignancy management moderate Necrosis offer outcome outcomes Patient power calculation Prevalence provide Region required retrospective cohort study Severe infection Standard deviation Statistical power stratified Surveillance therapeutic TNFα [DOI] 10.1007/s40259-021-00498-3 PMC 바로가기 [Article Type] Article
Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological DrugsObservational Study Published on 2021-08-272022-10-04 Journal: Medicina [Category] MERS, SARS, 임상, [키워드] Administered Affect analyzed Area Biological biological drugs chain comparable control group Course COVID-19 COVID-19 disease COVID-19 pandemic diagnosed drug effective therapy eight Hospitalization index infected with SARS-CoV-2 influence material Mild observé Patient PCR positive psoriasis psoriatic arthritis reaction required Result RT-PCR SARS-CoV-2 SARS-COV-2 infection skin lesions statistically telephone contact therapy time Treatment [DOI] 10.3390/medicina57090881 PMC 바로가기 [Article Type] Observational Study
Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO projectCOVID-19 감염에서 NO-cGMP-PDE5 경로를 표적으로 합니다. 데달로 프로젝트Article Published on 2021-01-012022-09-11 Journal: Andrology [Category] SARS, 임상, 치료제, [키워드] acting activated T cells administration alveolar ANG-II anti-inflammatory response biological drug biological drugs cause Cell cGMP clinical trial clotting Complication complications of COVID-19 contraindication contraindications COVID-19 COVID-19 disease COVID-19 infection cyclic GMP cytokine cytokine release Cytokine storm Cytokines diabete diabetes Diabetes Mellitus Diabetic diffusion disease downregulation drug dysregulation endothelial Endothelial cell endothelial cell damage Evidence expressed favor fibrosis IL-6 immune system implication IMPROVE infiltration inhibiting interstitial interstitial pneumonia limit Liver function low-grade inflammation Lungs material men mesenchymal cells Metabolic diseases modulating monocyte Necrosis nitric oxide Numerous offer ongoing trial ongoing trials outbreak oxygen pandemic pathophysiology pathway Patient patients with COVID-19 PDE5 inhibitor PDE5 inhibitors performed positive presenting pro-inflammatory cytokines pulmonary artery pulmonary fibrosis raise reducing renal impairment resource respiratory respiratory infection responsible severe COVID-19 disease Sildenafil smooth muscle smooth muscle cell smooth muscle cells stability storm switching systematic review systemic disease T cells targeting temperature thrombotic Thrombotic complications transition type 2 diabete Type 2 diabetes mellitus Vascular vessel widespread [DOI] 10.1111/andr.12837 PMC 바로가기 [Article Type] Article
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based reviewArticle Published on 2020-06-262023-06-15 Journal: Rheumatology International [Category] MERS, SARS, [키워드] ankylosing spondylitis biological drugs COVID-19 interleukin-17 Rheumatic diseases Secukinumab spondyloarthritis [DOI] 10.1007/s00296-020-04635-z PMC 바로가기